Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12107712 | 0.86 | SLC1A2 (0.40) | SLC1A2KMT2ATSHRNPSR1SMN1; SMN2 | |
| SCHEMBL18877419 | 0.83 | SMN1; SMN2 (0.41) | SLC1A2KMT2ATSHRSMN1; SMN2GAA | |
| SCHEMBL16652232 | 0.82 | TSHR (0.44) | SLC1A2KMT2ATSHRNPSR1SMN1; SMN2 | |
| SCHEMBL22343429 | 0.82 | TSHR (0.36) | SLC1A2TDP1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL13062617 | 0.82 | TP53 (0.38) | SLC1A2TDP1KMT2ATSHRNPSR1 | |
| SCHEMBL9457039 | 0.82 | SLC1A2 (0.40) | SLC1A2KMT2ATSHRNPSR1SMN1; SMN2 | |
| SCHEMBL17841877 | 0.81 | TERT (0.40) | SLC1A2KMT2ATSHRNPSR1SMN1; SMN2 | |
| SCHEMBL30269173 | 0.81 | TERT (0.40) | SLC1A2KMT2ATSHRNPSR1SMN1; SMN2 | |
| SCHEMBL19882338 | 0.80 | TSHR (0.35) | SLC1A2TDP1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL12109372 | 0.79 | ALDH1A1 (0.39) | SLC1A2KMT2ANPSR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835556-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2014-09-16 | — | — | US | disclosed |
| US-8288351-B2 | Antagonists of the bradykinin B1 receptor | AMGEN INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8278280-B2 | Antagonists of the bradykinin B1 receptor | AMGEN INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-09-06 | — | — | US | disclosed |
| US-8124791-B2 | Active energy ray curable liquid composition and liquid cartridge | CANON KABUSHIKI KAISHA (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8106131-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100094024-A1 | ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE | CANON KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090137483-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137452-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090048149-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090012241-A1 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432330-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048149-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, LTB4R | SLC1A2 2721/4885TDP1 4230/4885KMT2A 3538/4885 |
| US-20090137452-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, LTB4R | SLC1A2 2212/4885TDP1 4410/4885KMT2A 3599/4885 |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | PADI6, MPI, VIM | SLC1A2 3605/4885TDP1 719/4885KMT2A 984/4885 |
| US-20090137483-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, AVPR1B | SLC1A2 2302/4885TDP1 4424/4885KMT2A 3679/4885 |
| US-20100094024-A1 | ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE | C9, MLX, CHRM1 | SLC1A2 933/4885TDP1 3570/4885KMT2A 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.